CancerLinQ LLC and the International Association for the Study of Lung Cancer (IASLC) are collaborating to expand the specialized expertise informing CancerLinQ, a big data initiative focused on cancer patient medical information.
The IASLC will contribute thought leadership and subject matter expertise to CancerLinQ including aspects of clinical practice related to the diagnosis and management of lung cancer, the identification and development of clinical quality measures for thoracic oncology, and other relevant content.
CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO). The platform collects and analyzes real-world data from patients at practices nationwide with the goal of improving the quality of patient care and outcomes. The project also aims to deliver new insights from research and discovery.
The IASLC has a membership of more than 6,500 lung cancer specialists in over 100 countries, who work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. This engagement with CancerLinQ furthers the IASLC's mission to use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.
"The real-world cancer data that CancerLinQ collects contributes vital information to the oncology field across cancer types," said CancerLinQ CEO Cory Wiegert, in a statement. "This collaboration allows us to work with the IASLC as we analyze CancerLinQ's data on lung cancer, the most commonly occurring and lethal cancer worldwide."
The collaboration with the IASLC is just the latest for CancerLinQ, which since 2016 has entered into relationships with the American Academy of PAs, American College of Medical Genetics and Genomics, American Society of Radiation Oncology, Association for Molecular Pathology, Cancer Informatics for Cancer Centers, College of American Pathologists, DIA, Food and Drug Administration, Hematology/Oncology Pharmacy Association, National Cancer Institute, National Society of Genetic Counselors, Oncology Nursing Society, and Society of Gynecologic Oncology.
